News

Recent news about Panacea Venture and select portfolio companies

June 17, 2024

DZD Presents at ASM Microbe

DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference

June 17, 2024

DZD Presents at ASM Microbe

DZD Presents Direct-From-Blood, Rapid Antimicrobial Susceptibility Testing at the 2024 ASM Microbe conference

June 4, 2024

Now Available: Myrtelle ASGCT Symposium Presentation

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.

June 4, 2024

Now Available: Myrtelle ASGCT Symposium Presentation

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

May 20, 2024

Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

May 20, 2024

Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

May 7, 2024

Myrtelle to Host a Symposium on Canavan Disease Clinical Trial Updates and Future Directions for Oligodendrocyte Targeting AAVs at the American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore on Wednesday, May 8, 2024

Join Myrtelle Inc. at the ASGCT 27th Annual Meeting on May 8, 2024, in Baltimore, for a pivotal symposium on Canavan disease.

May 7, 2024

Myrtelle to Host a Symposium on Canavan Disease Clinical Trial Updates and Future Directions for Oligodendrocyte Targeting AAVs at the American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore on Wednesday, May 8, 2024

Join Myrtelle Inc. at the ASGCT 27th Annual Meeting on May 8, 2024, in Baltimore, for a pivotal symposium on Canavan disease.